Every material Form 8-K ScanSource has filed with the SEC since May 07, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ScanSource reported first-quarter fiscal 2027 net sales of $962.3 million, up 30.1% year over year, with GAAP net income down 56.3% to $8.7 million, or $0.42 per diluted share. The company raised its full-year fiscal 2027 outlook for net sales and adjusted EBITDA to include the MicroAge acquisition, which closed on September 1, 2026.
Net sales were $962.3 million, up 30.1%; gross profit margin fell to 12.2% from 14.5%.
GAAP diluted EPS was $0.42 versus $0.89 a year earlier; non-GAAP diluted EPS was $0.86 versus $1.06.
FY27 outlook raised to net sales of $3.8 billion to $4.0 billion and adjusted EBITDA of $175 million to $185 million, up from $158 million to $165 million.
Operating cash flow was negative $42.3 million, mainly from working capital investment; higher bad debt expense of about $4.5 million was tied mostly to Brazil.
On August 19, 2026, ScanSource agreed to acquire MicroAge, a technology provider, for $220.5 million in cash at closing, with closing expected in September 2026 subject to antitrust waiting-period expiration and third-party consents. On August 20, the company reported fourth-quarter fiscal 2026 net sales of $953.1 million, up 17.3%, and GAAP diluted EPS of $1.24 versus $0.88, and issued fiscal 2027 guidance that excludes the pending MicroAge deal.
Purchase price is $220.5 million in cash at closing, with $3 million in escrow for purchase price adjustments and $6.8 million for indemnification claims.
Q4 fiscal 2026 (quarter ended June 30, 2026): net sales $953.1 million, up 17.3%; GAAP diluted EPS $1.24 versus $0.88 a year earlier.
Fiscal 2026 GAAP net income was $78.9 million, or $3.64 per diluted share, versus $3.00; cash was $88.4 million and total debt was $101.4 million at June 30, 2026.
Fiscal 2027 outlook (excluding MicroAge): net sales growth of 6% to 10%, adjusted EBITDA of $158 million to $165 million, and free cash flow of at least $85 million.
Peter C. Browning, a ScanSource director since 2014, retired from the Board effective August 12, 2026, and the Board shrank to seven seats. The company said the move was not the result of any disagreement with Mr. Browning. The change is a board composition update rather than an executive or financial event.
Peter C. Browning notified the Board on August 11, 2026, and retired effective August 12, 2026.
Browning served as Lead Independent Director from February 2019 to January 2026.
The Board decreased in size to seven seats following his retirement.
The company said the transition is not the result of any disagreement with Mr. Browning.
ScanSource notified Rachel Hayden, its Senior Executive Vice President and Chief Information Officer, on May 22, 2026 that her role will be eliminated effective June 8, 2026. She is entitled to severance under the company's Executive Severance Plan and is subject to restrictive covenants in that plan, and the filing gives no replacement or financial figures.
Role of Senior Executive Vice President and Chief Information Officer eliminated effective June 8, 2026
Company notified Rachel Hayden on May 22, 2026
Hayden entitled to severance under the Executive Severance Plan, with non-compete and non-solicitation terms
Filing does not state a severance amount or a successor
ScanSource reported fiscal third-quarter 2026 net sales of $766.8 million, up 8.8% year over year, and GAAP diluted EPS of $0.78 versus $0.74. GAAP net income fell 3.1% to $16.9 million, and adjusted EBITDA rose 1.6% to $35.6 million, with its margin down to 4.65% from 4.97%. The company reaffirmed its net sales and adjusted EBITDA outlook for fiscal 2026 and raised its free cash flow outlook to at least $90 million.
Diluted EPS was $0.78 GAAP versus $0.74 a year earlier, and $0.94 non-GAAP versus $0.86, up 9.3%.
GAAP net income was $16.9 million, down 3.1%; adjusted EBITDA was $35.6 million, up 1.6%, with margin of 4.65% versus 4.97%.
Fiscal 2026 outlook reaffirmed: net sales of $3.0 billion to $3.1 billion and adjusted EBITDA of $140 million to $150 million.
Free cash flow outlook raised to at least $90 million from at least $80 million; share repurchases totaled $71.4 million in the first nine months of fiscal 2026.
ScanSource said Michael Webb will join on March 16, 2026 as Senior Executive Vice President and Chief Human Resources Officer. Alexandre Conde, the current Chief People Officer, will move to the role of Senior Executive Vice President, Strategy, effective the same date. The filing is an internal leadership change and does not include financial results or guidance.
Michael Webb hired March 6, 2026; starts March 16, 2026 as Senior EVP, Chief Human Resources Officer
Alexandre Conde changes role effective March 16, 2026, moving from Chief People Officer to Senior EVP, Strategy
Filing signed March 12, 2026 by President and CEO Michael L. Baur
ScanSource reported second-quarter fiscal 2026 net sales of $766.5 million, up 2.5% year over year, and GAAP diluted EPS of $0.75, up from $0.70, while non-GAAP diluted EPS fell to $0.80 from $0.85. The company replaced its prior fiscal 2026 outlook with lower net sales of $3.0 billion to $3.1 billion and lower adjusted EBITDA of $140 million to $150 million, so shareholders face a weaker full-year forecast despite higher quarterly sales.
Q2 net sales were $766.5 million, up 2.5%; adjusted EBITDA was $31.2 million, down 11.6%.
GAAP diluted EPS was $0.75 versus $0.70; non-GAAP diluted EPS was $0.80 versus $0.85.
FY26 net sales outlook cut to $3.0 billion to $3.1 billion from $3.1 billion to $3.3 billion.
FY26 adjusted EBITDA outlook cut to $140 million to $150 million from $150 million to $160 million; free cash flow outlook unchanged at at least $80 million.
ScanSource entered a new credit agreement with PNC Bank on December 18, 2025, providing a $400 million revolving credit facility and a $100 million term loan, and borrowed the full $100 million term loan that day. The company used the proceeds to repay and terminate its prior $500 million JPMorgan Chase credit agreement, which had been scheduled to expire or mature on September 28, 2027. The new facilities are secured by substantially all company and domestic subsidiary assets and carry leverage and interest coverage covenants.
New credit agreement with PNC Bank: $400 million five-year revolver plus $100 million five-year term loan, dated December 18, 2025
$100 million term loan drawn on December 18, 2025
Prior $500 million JPMorgan Chase credit agreement terminated and repaid on December 18, 2025
Covenants require leverage ratio of 3.50 to 1.00 or less and interest coverage of at least 3.00 to 1.00
ScanSource reported first-quarter fiscal 2026 results for the quarter ended September 30, 2025, with net sales down 4.6% year over year to $739.7 million while GAAP diluted EPS rose 29% to $0.89. The company reaffirmed its full-year fiscal 2026 outlook of $3.1 billion to $3.3 billion in net sales and $150 million to $160 million in adjusted EBITDA. Shareholders see lower sales offset by higher per-share profit, and the reaffirmed outlook means no change to guidance.
Net sales were $739.7 million, down 4.6% from $775.6 million a year earlier; gross profit rose 5.8% to $107.5 million.
GAAP net income was $19.9 million, or $0.89 per diluted share, versus $0.69 a year earlier; non-GAAP diluted EPS was $1.06, up 26.2%.
Share repurchases totaled $21.3 million in the quarter, and cash and cash equivalents were $124.9 million as of September 30, 2025.
FY26 outlook was reaffirmed: net sales of $3.1 billion to $3.3 billion, adjusted EBITDA of $150 million to $160 million, and free cash flow of at least $80 million.
ScanSource reported fourth-quarter and fiscal 2025 results for the year ended June 30, 2025. Q4 net sales rose 8.9% and GAAP diluted EPS rose to $0.88 from $0.64, while full-year net sales fell 6.7% and GAAP diluted EPS slipped to $3.00 from $3.06. The company also issued fiscal 2026 guidance calling for net sales of $3.1 billion to $3.3 billion and adjusted EBITDA of $150 million to $160 million.
Q4 FY25 net sales were $812.9 million, up 8.9% year over year, and GAAP diluted EPS was $0.88 versus $0.64.
FY25 net sales were $3.04 billion, down 6.7%, and GAAP diluted EPS was $3.00 versus $3.06; non-GAAP diluted EPS was $3.57 versus $3.08.
FY26 outlook: net sales of $3.1 billion to $3.3 billion, adjusted EBITDA of $150 million to $160 million, and free cash flow of at least $80 million.
At June 30, 2025, cash was $126.2 million and total debt was $136.1 million; FY25 share repurchases totaled $106.5 million.
ScanSource reported fiscal third-quarter 2025 net sales of $704.8 million, down 6.3% year over year, while GAAP diluted EPS rose to $0.74 from $0.50. The company replaced its fiscal 2025 outlook, now expecting net sales of approximately $3 billion and adjusted EBITDA of $140 million to $145 million, and announced a new $200 million share repurchase authorization.
Q3 net sales were $704.8 million, down 6.3%; GAAP net income was $17.4 million, or $0.74 per diluted share, versus $0.50 a year earlier
Non-GAAP diluted EPS was $0.86, up 24.6%; adjusted EBITDA rose 5.9% to $35.1 million
FY25 outlook: net sales of approximately $3 billion (prior $3.1 billion to $3.5 billion); adjusted EBITDA of $140 million to $145 million (prior $140 million to $160 million); free cash flow at least $70 million, unchanged
Board approved a new $200 million buyback; about $42 million remained under the existing authorization as of March 31, 2025
ScanSource reported fiscal second-quarter 2025 results for the quarter ended December 31, 2024, with net sales down 15.5% year over year and GAAP net income down 47.9%. The company reaffirmed its fiscal 2025 outlook and said its CEO, Mike Baur, was also appointed President effective January 27, 2025, with no change to his compensation.
Net sales were $747.5 million versus $884.8 million a year earlier; gross profit rose 1.0% to $101.7 million.
GAAP diluted EPS was $0.70 versus $1.29; non-GAAP diluted EPS was $0.85, unchanged year over year.
Fiscal 2025 outlook reaffirmed: net sales $3.1 billion to $3.5 billion and adjusted EBITDA $140 million to $160 million.
Mike Baur, Chair and CEO, was appointed President effective January 27, 2025, and his compensation will not change.
At its December 10, 2024 annual meeting, ScanSource shareholders approved the 2024 Omnibus Incentive Compensation Plan, which replaces the 2021 plan for future grants. All eight director nominees were elected, and shareholders also approved the advisory say-on-pay vote and ratified Grant Thornton LLP as auditors for fiscal 2025.
2024 Plan reserves 2,234,543 shares of common stock for awards, plus shares from 2021 Plan awards that later become available
No further awards will be granted under the 2021 Plan; outstanding 2021 awards continue under their terms
Plan approval received 19,590,961 for votes and 1,215,191 against votes
Shareholders represented by proxy held 89.5% of outstanding common stock, or 21,501,384 shares
ScanSource reported fiscal first-quarter 2025 results for the quarter ended September 30, 2024, with net sales down 11.5% to $775.6 million and GAAP diluted EPS up 13.1% to $0.69. GAAP operating income fell 26.8% to $17.6 million, and the company reaffirmed its fiscal 2025 annual outlook without change. For shareholders, per-share profit rose on lower sales, while the sales decline and operating income drop show a weaker underlying operating trend.
Net sales were $775.6 million, down 11.5% year over year; non-GAAP net sales, excluding currency and acquisitions, fell 10.7%.
GAAP diluted EPS was $0.69 versus $0.61; non-GAAP diluted EPS was $0.84 versus $0.74.
GAAP operating income was $17.6 million versus $24.1 million, including $5.1 million in restructuring and other charges.
Fiscal 2025 outlook was reaffirmed: net sales $3.1 billion to $3.5 billion, adjusted EBITDA $140 million to $160 million, and free cash flow of at least $70 million.
ScanSource reported fourth-quarter and fiscal 2024 results for the year ended June 30, 2024, with net sales down 21.2% in the quarter and 13.9% for the year, and GAAP diluted EPS down year over year. The company also issued its first fiscal 2025 outlook, projecting net sales of $3.1 billion to $3.5 billion and adjusted EBITDA of $140 million to $160 million, and said it completed two acquisitions in August 2024.
Q4 fiscal 2024 net sales were $746.1 million, down 21.2%, and GAAP diluted EPS was $0.64 versus $0.68 a year earlier.
Fiscal 2024 GAAP diluted EPS was $3.06 versus $3.47, and operating cash flow was $371.6 million versus a $35.8 million outflow.
FY25 outlook: net sales $3.1 billion to $3.5 billion, adjusted EBITDA $140 million to $160 million, and free cash flow of at least $70 million.
ScanSource reported third-quarter fiscal 2024 net sales of $752.6 million, down 15.0% year over year, and GAAP diluted EPS of $0.50, down from $0.83. The company lowered its full-year fiscal 2024 guidance for net sales, adjusted EBITDA and free cash flow was raised, and it announced a new $100 million share repurchase authorization.
Q3 net sales $752.6 million, down 15.0%; GAAP net income $12.8 million, down 39.7%
FY24 net sales outlook cut to at least $3.3 billion from at least $3.5 billion; adjusted EBITDA cut to at least $140 million from at least $155 million
FY24 free cash flow outlook raised to at least $275 million from at least $200 million
New $100 million share repurchase authorization; about $45 million remained under the prior authorization as of March 31, 2024
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ScanSource filing is on SEC EDGAR ↗. 8-K briefs of other companies →